Skip to main content
Premium Trial:

Request an Annual Quote

Roche Acquires NGS Target-Enrichment Tech from AbVitro

NEW YORK (GenomeWeb) – Roche said today that it has acquired the exclusive rights to next-generation sequencing target enrichment technology from AbVitro, a company focused on therapeutic target discovery.

Under the terms of the agreement, the two companies will collaborate to develop the technology, called primer extension-based target enrichment (PETE). Roche plans to use PETE to support next-generation sequencing directly from blood or other biological samples. In addition, Roche will incorporate the PETE technology into the Roche Sequencing Unit R&D pipeline to support its clinical sequencing strategy.

"The potential of this technology will allow Roche to optimize our sequencing portfolio to provide a full workflow solution for our customers," Dan Zabrowski, head of Roche Tissue Diagnostics and the Sequencing Unit, said in a statement. "We look forward to advancing this technology in order to streamline sequencing methods for easy-to-use clinical applications."

Francois Vigneault, president, CSO and co-founder of AbVitro, added in a statement that the technology "surpasses current industry standards and we believe Roche to be incredibly well positioned to create a true disruption in the next-generation sample prep market."

AbVitro is developing single-cell immune sequencing technology based on work by co-founder George Church of Harvard Medical School. According to the company, the platform enables the identification of complete natively paired B-cell antibodies and T-cell receptors across millions of single cells and can then be used to identify novel therapeutic targets and antibodies to cancer and autoimmune diseases.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.